Sales of Fuzeon much lower than analysts expected
February 07 2004 12:00 AM ET
Sales of the HIV fusion inhibitor Fuzeon, developed by Trimeris and Roche, are much lower than many industry analysts expected, The [Raleigh, N.C.] News and Observer reports. Fuzeon, the first anti-HIV medication that works by preventing HIV from entering immune system cells, carries an annual price tag of about $20,000. Analysts report that doctors and patients have been more reluctant to prescribe and take the injectable medication because of its high cost. More patients than expected who began Fuzeon treatment also stopped taking the drug, according to reports. The patient drop-out rate has been more than 25%, more than double what had been predicted. Sales of the medication were about 9,000 prescriptions in the fourth quarter of 2003. To increase interest in and sales of the drug, Roche has planned an education campaign for doctors, nurses, and patients as well as post-marketing studies comparing the drug to other anti-HIV treatments.
- Holiday Guide: Shop Here, Not There
- WATCH: Jared Leto on Avoiding Trans Character 'Cliché' for 'Dallas Buyers Club'
- New Celeb Couple: Dustin Lance Black and Tom Daley
- Op-ed: Straight Teen Girls Can Change the World
- Bringing Diversity to the Digital Realm
- Gay News, LGBT Rights, Politics, Entertainment | The Advocate
- Travel Out Traveler Awards: Best Cruise Line? 21 min 36 sec ago
- Society Making LGBT Spirits Bright This Holiday Season 22 min 29 sec ago
- Women PHOTOS: Oxford University's Women's Rugby Club Bares All for Charity 38 min 17 sec ago
- Entertainment News Bill Hader Wanted Stefon's Goodbye to Be Emotional 4:50 PM
- Women 13 Reasons to Let AHS: Coven Cast A Spell on You -- in GIFs 4:36 PM
- Sports You Can Play and NFL Team Up With LGBT Youth 3:37 PM
- Entertainment News Gay Men's Chorus of Los Angeles Performs Parody of Joe Boxer Christmas Ad 3:36 PM